pISSN 1226-6051
eISSN 2508-786X

Table. 1.

Table. 1.

The distribution of severity of drug-drug interaction between drug databases (N=627)

Lexicomp® Micromedex®

Severity N (%) Contraindicated Major Moderate Minor No DDI information No drug information

N (%) N (%) N (%) N (%) N (%) N (%)
Overall 627 (100.0) 10 (1.6) 413 (65.9) 15 (2.4) 0 (0.0) 83 (13.2) 106 (16.9)
X 159 (25.4) 3 (1.9) 86 (54.1) 0 (0.0) 0 (0.0) 28 (17.6) 42 (26.4)
D 265 (42.3) 5 (1.9) 126 (47.5) 15 (5.7) 0 (0.0) 55 (20.8) 64 (24.2)
C 131 (20.9) 2 (1.5) 129 (92.8) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
B 16 (2.6) 0 (0.0) 16 (100) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
No DDI information 48 (7.7) 0 (0.0) 48 (100.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
No drug information 8 (1.3) 0 (0.0) 8 (100.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)

with generic 64 (100.0) 0 (0.0) 47 (73.4) 0 (0.0) 0 (0.0) 12 (18.8) 5 (7.8)
X 4 (6.3) 0 (0.0) 3 (75.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (25.0)
D 46 (71.9) 0 (0.0) 30 (65.2) 0 (0.0) 0 (0.0) 12 (26.1) 4 (8.7)
C 8 (12.5) 0 (0.0) 8 (100.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
B 0 (0.0) 0 - 0 - 0 - 0 - 0 - 0 -
No DDI information 4 (6.3) 0 (0.0) 4 100.0 0 0.0 0 (0.0) 0 (0.0) 0 (0.0)
No drug information 2 (3.1) 0 (0.0) 2 100.0 0 0.0 0 (0.0) 0 (0.0) 0 (0.0)

without generic 563 (100.0) 10 (1.8) 366 (65.0) 15 (2.7) 0 (0.0) 71 (12.6) 101 (17.9)
X 155 (27.5) 3 (1.9) 83 (53.5) 0 (0.0) 0 (0.0) 28 (18.1) 41 (26.5)
D 219 (38.9) 5 (2.3) 96 (43.8) 15 (6.8) 0 (0.0) 42 (19.6) 60 (27.4)
C 123 (21.8) 2 (1.6) 121 (98.4) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
B 16 (2.8) 0 (0.0) 16 (100.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
No DDI information 44 (7.8) 0 (0.0) 44 (100.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
No drug information 6 (1.1) 0 (0.0) 6 (100.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)

Gray area: The severity of DDI combinations was identified with two databases (Total=382, with generic=41, without generic=341).

The distribution of severity of DDI combinations was significantly different between tyrosine kinase inhibitors with generics and without generics in Lexicomp® database (p<0.001)

DDI: Drug-drug interaction

Korean J Clin Pharm 2020;30:44-50 https://doi.org/10.24304/kjcp.2020.30.1.44
© 2020 Korean J Clin Pharm